These programs include (1) the concurrent genetic and epigenetic disruption of the MHC proteins, (2) diminished expression of wild-type antigens via de-differentiation and tumor-intrinsic IFNγ signaling, and (3) immune cell exclusion associated with PTEN loss and brain metastasis. This evidence concerns the gene PTEN and neoplasm.